Earnings Release • Nov 13, 2014
Earnings Release
Open in ViewerOpens in native device viewer
Libourne – 13 November 2014 – Fermentalg, an industrial biotechnology company that specializes in the production of oils and proteins derived from microalgae, has published its financial information for the third quarter of 2014. Highlights for the period include:
Fermentalg has obtained the building permit for a new Industrial Development Unit (IDU) at its site in Libourne (33). Preparatory work has begun, and the unit is scheduled to be commissioned at the end of 2015.
Fermentalg's future entry into the industrial production of microalgae made possible by the funds raised during its IPO has given the company the means to reinforce its business development policy.
On 10 July, Fermentalg and Sofiprotéol also announced a new agreement in their partnership for the production and sale of Omega-3. Several covenants were signed, notably whereby the programme's industrial processes and resources will henceforth be managed by Fermentalg at the IDU. Oleon (a subsidiary of Sofiprotéol) will act as nonexclusive distributor for the products manufactured by Fermentalg within the IDU.
Financial contributions by Fermentalg's partners amounted to €225,000 for the third quarter of 2014 versus €0 for the same period in 2013. Revenues for the first 9 months of the year came in at €675,000 as against €0 for the first 9 months of 2013.
At 30 September 2014, Fermentalg's gross cash position amounted to €41.9 million, and the Group's financial resources are fully in line with its business development strategy.
| Turnover (in € thousand)- Pre-audit IFRS figures |
2013 | 2014 |
|---|---|---|
| 1st half | 0 | 450 |
| 3rd quarter | 0 | 225 |
| 9 months | 0 | 675 |
The third quarter of 2014 saw Fermentalg reinforce its barriers-to-entry in the field of microalgae. The company was awarded its first active ingredient patent to protect its stateof-the-art technology (breeding of microalgae in a predominantly heterotrophic mixotrophic environment), adding yet another building block to the Group's extensive portfolio of intellectual rights which included 25 families of patents on 30 September 2014.
In order to maintain its technological head start, Fermentalg has also strengthened its team of scientists with the appointment of Dr. Hywel Griffiths (PhD) to the position of VP R&D. With a degree and PhD in molecular microbiology from the University of Cambridge, Hywel Griffiths is a world-renowned specialist in microalgae. In 2013, he was named "Young Biotechnologist of the Year" at the NZBIO annual awards ceremony.
Founded in 2009 by Pierre Calleja, Fermentalg is an industrial biotechnology company that specializes in producing sustainable oils and proteins derived from the exceptional properties of microalgae. Its patented technology allows it to target a range of fast-growing global markets, from nutrition and animal feed to cosmetics and health, green chemistry and energy. Fermentalg has already signed its 1st industrial and commercial joint-venture for the production of Omega-3 oils rich in EPA and DHA as well as several other partnerships with leading industrial groups. Fermentalg shares are listed on Euronext in Paris (FR0011271600 - FALG). For more information, visit the Fermentalg website at: www.fermentalg.com.
ACTUS finance & communication Alexandra Prisa Tel: +33 (0)1 53 67 35 79 [email protected]
ACTUS finance & communication Jérôme Fabreguettes-Leib Tel: +33 (0)1 77 35 04 36 [email protected]
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.